DBV Technologies | DBVT - Stammkapital





Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amarin USD 20.81M 13K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
DBV Technologies USD 235.6M 98.78M 2025-12
Galectin Therapeutics USD 61K 0 2023-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Incyte USD 200.98M 1.03M 2026-06
Insmed USD 216.52M 2.27M 2026-03
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Neurocrine Biosciences USD 100.55M 50K 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
United Therapeutics USD 42.16M 1.49M 2026-03